BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) +- chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
Cetuximab;Encorafenib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) +- chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). ### Output: Cetuximab;Encorafenib